Advancements in neurotherapeutics: nanoparticles overcoming the blood–brain barrier for precise CNS targeting
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Barrier Structure and Function Studies · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Sweeney MD, Zhao Z, Montagne A, Nelson AR, Zlokovic BV (2019) Blood-Brain barrier: from physiology to disease and back. Physiol Rev 99(1):21–7810.1152/physrev.00050.2017 ↗
2. Ames AD, Coogan S, Egerstedt M, Notomista G, Sreenath K, Tabuada P, editors. Control barrier functions: theory and applications2019: IEEE10.23919/ECC.2019.8796030 ↗
3. Daneman R, Prat A (2015) The blood-brain barrier. Cold Spring Harb Perspect Biol 7(1):a02041210.1101/cshperspect.a020412 ↗
4. Weiss N, Miller F, Cazaubon S, Couraud PO (2009) The blood-brain barrier in brain homeostasis and neurological diseases. Biochim Biophys Acta 1788(4):842–85710.1016/j.bbamem.2008.10.022 ↗
5. Nguyen TT, Duong VA, Maeng HJ (2021) Pharmaceutical formulations with P-Glycoprotein inhibitory effect as promising approaches for enhancing oral drug absorption and bioavailability. Pharmaceutics 13:7
6. Amin ML (2013) P-glycoprotein inhibition for optimal drug delivery. Drug Target Insights 7:27–34
7. Halder J, Pradhan D, Kar B, Ghosh G, Rath G (2022) Nanotherapeutics approaches to overcome P-glycoprotein-mediated multi-drug resistance in cancer. Nanomedicine 40:10249410.1016/j.nano.2021.102494 ↗
8. Annu Sartaj A, Qamar Z, Md S, Alhakamy NA, Baboota S et al (2022) An insight to brain targeting utilizing polymeric nanoparticles: effective treatment modalities for neurological disorders and brain tumor. Front Bioeng Biotechnol 10:78812810.3389/fbioe.2022.788128 ↗
9. Yang J, Luly KM, Green JJ (2023) Nonviral nanoparticle gene delivery into the CNS for neurological disorders and brain cancer applications. WIREs Nanomed Nanobiotechnol 15(2):e185310.1002/wnan.1853 ↗
10. Yusuf A, Almotairy ARZ, Henidi H, Alshehri OY, Aldughaim MS (2023) Nanoparticles as drug delivery systems: a review of the implication of nanoparticlesʼ physicochemical properties on responses in biological systems. Polymers [Internet] 15:7
11. Hersh AM, Alomari S, Tyler BM (2022) Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int J Mol Sci 23:810.3390/ijms23084153 ↗
12. Thangudu S, Cheng FY, Su CH (2020) Advancements in the blood-brain barrier penetrating nanoplatforms for brain related disease diagnostics and therapeutic applications. Polymers (Basel) 12:1210.3390/polym12123055 ↗
13. Caraway CA, Gaitsch H, Wicks EE, Kalluri A, Kunadi N, Tyler BM (2022) Polymeric nanoparticles in brain cancer therapy: a review of current approaches. Polymers (Basel) 14:1410.3390/polym14142963 ↗
14. Quader S, Kataoka K, Cabral H (2022) Nanomedicine for brain cancer. Adv Drug Deliv Rev 182:11411510.1016/j.addr.2022.114115 ↗
15. Bhargav AG, Mondal SK, Garcia CA, Green JJ, Quiñones-Hinojosa A (2020) Nanomedicine revisited: next generation therapies for brain cancer. Advanced Therapeutics 3(10):200011810.1002/adtp.202000118 ↗
16. Yildirimer L, Thanh NT, Loizidou M, Seifalian AM (2011) Toxicology and clinical potential of nanoparticles. Nano Today 6(6):585–60710.1016/j.nantod.2011.10.001 ↗
17. Cheng T-M, Chu H-Y, Huang H-M, Li Z-L, Chen C-Y, Shih Y-J et al (2022) Toxicologic concerns with current medical nanoparticles. Int J Mol Sci [Internet. 23:14
18. Abbasi R, Shineh G, Mobaraki M, Doughty S, Tayebi L (2023) Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review. J Nanopart Res 25(3):4310.1007/s11051-023-05690-w ↗
19. Kang K, Jung H, Lim JS (2012) Cell death by polyvinylpyrrolidine-coated silver nanoparticles is mediated by ROS-dependent signaling. Biomol Ther (Seoul) 20(4):399–40510.4062/biomolther.2012.20.4.399 ↗
20. Akter M, Sikder MT, Rahman MM, Ullah AKMA, Hossain KFB, Banik S et al (2018) A systematic review on silver nanoparticles-induced cytotoxicity: physicochemical properties and perspectives. J Adv Res 9:1–1610.1016/j.jare.2017.10.008 ↗
21. Facciolà A, Visalli G, La Maestra S, Ceccarelli M, D’Aleo F, Nunnari G et al (2019) Carbon nanotubes and central nervous system: environmental risks, toxicological aspects and future perspectives. Environ Toxicol Pharmacol 65:23–3010.1016/j.etap.2018.11.006 ↗
22. Ajdary M, Moosavi MA, Rahmati M, Falahati M, Mahboubi M, Mandegary A et al (2018) Health concerns of various nanoparticles: a review of their in vitro and in vivo toxicity. Nanomaterials (Basel). 8:910.3390/nano8090634 ↗
23. Egbuna C, Parmar VK, Jeevanandam J, Ezzat SM, Patrick-Iwuanyanwu KC, Adetunji CO et al (2021) Toxicity of nanoparticles in biomedical application: nanotoxicology. J Toxicol 2021:995444310.1155/2021/9954443 ↗
24. Zhang N, Xiong G, Liu Z (2022) Toxicity of metal-based nanoparticles: challenges in the nano era. Front Bioeng Biotechnol 10:100157210.3389/fbioe.2022.1001572 ↗
25. Ribovski L, Hamelmann NM, Paulusse JMJ (2021) Polymeric nanoparticles properties and brain delivery. Pharmaceutics 13:1210.3390/pharmaceutics13122045 ↗
26. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L (2016) Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release 235:34–4710.1016/j.jconrel.2016.05.044 ↗
27. Nogueira DR, Mitjans M, Rolim CM, Vinardell MP (2014) Mechanisms underlying cytotoxicity induced by engineered nanomaterials: a review of in vitro studies. Nanomaterials (Basel) 4(2):454–48410.3390/nano4020454 ↗
28. Li Y, Zhang Y, Yan B (2014) Nanotoxicity overview: nano-threat to susceptible populations. Int J Mol Sci 15(3):3671–369710.3390/ijms15033671 ↗
29. Yang W, Wang L, Mettenbrink EM, DeAngelis PL, Wilhelm S (2021) Nanoparticle toxicology. Annu Rev Pharmacol Toxicol 61(1):269–28910.1146/annurev-pharmtox-032320-110338 ↗
30. Gornati R, Papis E, Di Gioacchino M, Sabbioni E, Dalle Donne I, Milzani A et al (2009) In vivo and in vitro models for nanotoxicology testing. John Wiley & Sons, Ltd, Chichester, pp 279–30210.1002/9780470747803.ch15 ↗
31. Akçan R, Aydogan HC, Yildirim M, Taştekin B, Sağlam N (2020) Nanotoxicity: a challenge for future medicine. Turk J Med Sci 50(4):1180–119610.3906/sag-1912-209 ↗
32. Yang Z, Liu ZW, Allaker RP, Reip P, Oxford J, Ahmad Z et al (2010) A review of nanoparticle functionality and toxicity on the central nervous system. J R Soc Interface 7(Suppl 4):S411-22
33. Patel T, Zhou J, Piepmeier JM, Saltzman WM (2012) Polymeric nanoparticles for drug delivery to the central nervous system. Adv Drug Deliv Rev 64(7):701–70510.1016/j.addr.2011.12.006 ↗
34. Keller BL, Lohmann CA, Kyeremateng SO, Fricker G (2022) Synthesis and characterization of biodegradable poly(butyl cyanoacrylate) for drug delivery applications. Polymers (Basel) 14:510.3390/polym14050998 ↗
35. Thammasit P, Tharinjaroen CS, Tragoolpua Y, Rickerts V, Georgieva R, Bäumler H et al (2021) Targeted propolis-loaded poly (butyl) cyanoacrylate nanoparticles: an alternative drug delivery tool for the treatment of cryptococcal meningitis. Front Pharmacol 12:72372710.3389/fphar.2021.723727 ↗
36. Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ (2022) On a highway to the brain: a review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today 29:10163110.1016/j.apmt.2022.101631 ↗
37. Ding S, Khan AI, Cai X, Song Y, Lyu Z, Du D et al (2020) Overcoming blood-brain barrier transport: advances in nanoparticle-based drug delivery strategies. Mater Today (Kidlington) 37:112–12510.1016/j.mattod.2020.02.001 ↗
38. Xie J, Shen Z, Anraku Y, Kataoka K, Chen X (2019) Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials 224:11949110.1016/j.biomaterials.2019.119491 ↗
39. Teleanu RI, Preda MD, Niculescu AG, Vladâcenco O, Radu CI, Grumezescu AM et al (2022) Current strategies to enhance delivery of drugs across the blood-brain barrier. Pharmaceutics 14:510.3390/pharmaceutics14050987 ↗
40. Mishra A, Kumar R, Mishra J, Dutta K, Ahlawat P, Kumar A et al (2023) Strategies facilitating the permeation of nanoparticles through blood-brain barrier: an insight towards the development of brain-targeted drug delivery system. J Drug Deliv Sci Technol 86:10469410.1016/j.jddst.2023.104694 ↗
41. Ndemazie NB, Inkoom A, Morfaw EF, Smith T, Aghimien M, Ebesoh D et al (2021) Multi-disciplinary approach for drug and gene delivery systems to the brain. AAPS PharmSciTech 23(1):1110.1208/s12249-021-02144-1 ↗
42. Johnsen KB, Burkhart A, Thomsen LB, Andresen TL, Moos T (2019) Targeting the transferrin receptor for brain drug delivery. Prog Neurobiol 181:10166510.1016/j.pneurobio.2019.101665 ↗
43. Vanbilloen WJF, Rechberger JS, Anderson JB, Nonnenbroich LF, Zhang L, Daniels DJ (2023) Nanoparticle strategies to improve the delivery of anticancer drugs across the blood–brain barrier to treat brain tumors. Pharmaceutics [Internet]. 15:7
44. Pinheiro RGR, Coutinho AJ, Pinheiro M, Neves AR (2021) Nanoparticles for targeted brain drug delivery: what do we know? Int J Mol Sci 22:21
45. Parvez S, Kaushik M, Ali M, Alam MM, Ali J, Tabassum H et al (2022) Dodging blood brain barrier with “nano” warriors: novel strategy against ischemic stroke. Theranostics 12(2):689–71910.7150/thno.64806 ↗
46. Sethi B, Kumar V, Mahato K, Coulter DW, Mahato RI (2022) Recent advances in drug delivery and targeting to the brain. J Control Release 350:668–68710.1016/j.jconrel.2022.08.051 ↗
47. Joseph TM, KarMahapatra D, Esmaeili A, Piszczyk Ł, Hasanin MS, Kattali M et al (2023) Nanoparticles: taking a unique position in medicine. Nanomaterials [Internet] 13:3
48. Alahmari A (2021) Blood-brain barrier overview: structural and functional correlation. Neural Plast 2021:656458510.1155/2021/6564585 ↗
49. Villabona-Rueda A, Erice C, Pardo CA, Stins MF (2019) The evolving concept of the blood brain barrier (BBB): from a single static barrier to a heterogeneous and dynamic relay center. Front Cell Neurosci 13:40510.3389/fncel.2019.00405 ↗
50. Smith QR (2003) A review of blood-brain barrier transport techniques. The Blood-Brain Barrier: Biol Res Protoc 193–20810.1385/1-59259-419-0:193 ↗
51. Knox EG, Aburto MR, Clarke G, Cryan JF, O’Driscoll CM (2022) The blood-brain barrier in aging and neurodegeneration. Mol Psychiatry 27(6):2659–267310.1038/s41380-022-01511-z ↗
52. Han G, Song L, Ding Z, Wang Q, Yan Y, Huang J et al (2022) The important double-edged role of astrocytes in neurovascular unit after ischemic stroke. Front Aging Neurosci 14:83343110.3389/fnagi.2022.833431 ↗
53. Bergers G, Song S (2005) The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol 7(4):452–46410.1215/S1152851705000232 ↗
54. Armulik A, Genové G, Mäe M, Nisancioglu MH, Wallgard E, Niaudet C et al (2010) Pericytes regulate the blood-brain barrier. Nature 468(7323):557–56110.1038/nature09522 ↗
55. Chaulagain B, Gothwal A, Lamptey RN, Trivedi R, Mahanta AK, Layek B et al (2023) Experimental models of in vitro blood–brain barrier for CNS drug delivery: an evolutionary perspective. Int J Mol Sci [Internet]. 24:3
56. Partridge B, Eardley A, Morales BE, Campelo SN, Lorenzo MF, Mehta JN et al (2022) Advancements in drug delivery methods for the treatment of brain disease. Front Vet Sci 9:103974510.3389/fvets.2022.1039745 ↗
57. Ayub A, Wettig S (2022) An overview of nanotechnologies for drug delivery to the brain. Pharmaceutics 14:210.3390/pharmaceutics14020224 ↗
58. Afzal O, Altamimi ASA, Nadeem MS, Alzarea SI, Almalki WH, Tariq A et al (2022) Nanoparticles in drug delivery: from history to therapeutic applications. Nanomaterials (Basel) 12:2410.3390/nano12244494 ↗
59. Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MdP, Acosta-Torres LS et al (2018) Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol 16(1):7110.1186/s12951-018-0392-8 ↗
60. Mitchell MJ, Billingsley MM, Haley RM, Wechsler ME, Peppas NA, Langer R (2021) Engineering precision nanoparticles for drug delivery. Nat Rev Drug Discovery 20(2):101–12410.1038/s41573-020-0090-8 ↗
61. Bai X, Smith ZL, Wang Y, Butterworth S, Tirella A (2022) Sustained drug release from smart nanoparticles in cancer therapy: a comprehensive review. Micromachines (Basel) 13:10
62. Jalili C, Kiani A, Gholami M, Bahrehmand F, Fakhri S, Kakehbaraei S et al (2023) Brain targeting based nanocarriers loaded with resveratrol in Alzheimerʼs disease: a review. IET Nanobiotechnol 17(3):154–17010.1049/nbt2.12127 ↗
63. Maher R, Moreno-Borrallo A, Jindal D, Mai BT, Ruiz-Hernandez E, Harkin A (2023) Intranasal polymeric and lipid-based nanocarriers for CNS drug delivery. Pharmaceutics [Internet] 15:3
64. Mitusova K, Peltek OO, Karpov TE, Muslimov AR, Zyuzin MV, Timin AS (2022) Overcoming the blood–brain barrier for the therapy of malignant brain tumor: current status and prospects of drug delivery approaches. J Nanobiotechnol 20(1):41210.1186/s12951-022-01610-7 ↗
65. Palan F, Chatterjee B (2022) Dendrimers in the context of targeting central nervous system disorders. J Drug Deliv Sci Technol 73:10347410.1016/j.jddst.2022.103474 ↗
66. Zhu Y, Liu C, Pang Z (2019) Dendrimer-based drug delivery systems for brain targeting. Biomolecules 9:1210.3390/biom9010012 ↗
67. Pérez-Carrión MD, Posadas I (2023) Dendrimers in neurodegenerative diseases. Processes [Internet] 11:2
68. Ijaz H, Mahmood A, Abdel-Daim MM, Muhammad Sarfraz R, Zaman M, Zafar N et al (2023) Review on carbon nanotubes (CNTs) and their chemical and physical characteristics, with particular emphasis on potential applications in biomedicine. Inorg Chem Commun 155:11102010.1016/j.inoche.2023.111020 ↗
69. Debnath SK, Srivastava R (2021) Drug delivery with carbon-based nanomaterials as versatile nanocarriers: progress and prospects. Front Nanotechnol 3:64456410.3389/fnano.2021.644564 ↗
70. Yetisgin AA, Cetinel S, Zuvin M, Kosar A, Kutlu O (2020) Therapeutic nanoparticles and their targeted delivery applications. Molecules 25:910.3390/molecules25092193 ↗
71. Naqvi S, Panghal A, Flora SJS (2020) Nanotechnology: a promising approach for delivery of neuroprotective drugs. Front Neurosci 14:49410.3389/fnins.2020.00494 ↗
72. Chopra H, Bibi S, Singh I, Kamal MA, Islam F, Alhumaydhi FA et al (2022) Nanomedicines in the management of Alzheimer’s disease: current view and future prospects. Front Aging Neurosci 14:87911410.3389/fnagi.2022.879114 ↗
73. Miao YB, Zhao W, Renchi G, Gong Y, Shi Y (2023) Customizing delivery nano-vehicles for precise brain tumor therapy. J Nanobiotechnology 21(1):3210.1186/s12951-023-01775-9 ↗
74. Khambhla E, Shah V, Baviskar K (2016) Drug delivery to CNS: challenges and opportunities with emphasis on biomaterials based drug delivery strategies. Curr Pharm Des 22(19):2913–292210.2174/1381612822666160401145951 ↗
75. Achar A, Myers R, Ghosh C (2021) Drug delivery challenges in brain disorders across the blood-brain barrier: novel methods and future considerations for improved therapy. Biomedicines 9:1210.3390/biomedicines9121834 ↗
76. Archie SR, Al Shoyaib A, Cucullo L (2021) Blood-brain barrier dysfunction in CNS disorders and putative therapeutic targets: an overview. Pharmaceutics 13:1110.3390/pharmaceutics13111779 ↗
77. Jena L, McErlean E, McCarthy H (2020) Delivery across the blood-brain barrier: nanomedicine for glioblastoma multiforme. Drug Deliv Transl Res 10(2):304–31810.1007/s13346-019-00679-2 ↗
78. Wu D, Chen Q, Chen X, Han F, Chen Z, Wang Y (2023) The blood–brain barrier: structure, regulation, and drug delivery. Signal Transduct Target Ther 8(1):21710.1038/s41392-023-01481-w ↗
79. Khatami SH, Karami N, Taheri-Anganeh M, Taghvimi S, Tondro G, Khorsand M et al (2023) Exosomes: promising delivery tools for overcoming blood-brain barrier and glioblastoma therapy. Mol Neurobiol 60(8):4659–467810.1007/s12035-023-03365-0 ↗
80. Griffith JI, Rathi S, Zhang W, Zhang W, Drewes LR, Sarkaria JN et al (2020) Addressing BBB heterogeneity: a new paradigm for drug delivery to brain tumors. Pharmaceutics 12:1210.3390/pharmaceutics12121205 ↗
81. Rhaman MM, Islam MR, Akash S, Mim M, Noor Alam M, Nepovimova E et al (2022) Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: at a glance. Front Cell Dev Biol 10:98947110.3389/fcell.2022.989471 ↗
82. Patel V, Chavda V, Shah J (2021) Nanotherapeutics in neuropathologies: obstacles, challenges and recent advancements in CNS targeted drug delivery systems. Curr Neuropharmacol 19(5):693–71010.2174/1570159X18666200807143526 ↗
83. Georgieva JV, Hoekstra D, Zuhorn IS (2014) Smuggling drugs into the brain: an overview of ligands targeting transcytosis for drug delivery across the blood-brain barrier. Pharmaceutics 6(4):557–58310.3390/pharmaceutics6040557 ↗
84. Trevino JT, Quispe RC, Khan F, Novak V (2020) Non-invasive strategies for nose-to-brain drug delivery. J Clin Trials 10:7
85. Luo H, Shusta EV (2020) Blood-brain barrier modulation to improve glioma drug delivery. Pharmaceutics 12:11
86. Zhou L, Kodidela S, Godse S, Thomas-Gooch S, Kumar A, Raji B et al (2022) Targeted drug delivery to the central nervous system using extracellular vesicles. Pharmaceuticals (Basel) 15:3
87. Shreffler JW, Pullan JE, Dailey KM, Mallik S, Brooks AE (2019) Overcoming hurdles in nanoparticle clinical translation: the influence of experimental design and surface modification. Int J Mol Sci 20:2310.3390/ijms20236056 ↗
88. Agrahari V, Agrahari V (2018) Facilitating the translation of nanomedicines to a clinical product: challenges and opportunities. Drug Discov Today 23(5):974–99110.1016/j.drudis.2018.01.047 ↗
89. Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J (2022) Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnol 20(1):39510.1186/s12951-022-01605-4 ↗
90. Wu J (2021) The enhanced permeability and retention (EPR) effect: the significance of the concept and methods to enhance its application. J Pers Med 11:8
91. Hersh AM, Alomari S, Tyler BM (2022) Crossing the blood-brain barrier: advances in nanoparticle technology for drug delivery in neuro-oncology. Int J Mol Sci [Internet] 23:8
92. Nunes D, Loureiro JA, Pereira MC (2022) Drug delivery systems as a strategy to improve the efficacy of FDA-approved Alzheimerʼs drugs. Pharmaceutics [Internet] 14:11
93. Fernandes F, Dias-Teixeira M, Delerue-Matos C, Grosso C (2021) Critical review of lipid-based nanoparticles as carriers of neuroprotective drugs and extracts. Nanomaterials (Basel) 11:3
94. Zielińska A, Carreiró F, Oliveira AM, Neves A, Pires B, Venkatesh DN et al (2020) Polymeric nanoparticles: production, characterization, toxicology and ecotoxicology. Molecules 25:16
95. Zare H, Ahmadi S, Ghasemi A, Ghanbari M, Rabiee N, Bagherzadeh M et al (2021) Carbon nanotubes: smart drug/gene delivery carriers. Int J Nanomedicine 16:1681–170610.2147/IJN.S299448 ↗
96. Teixeira MI, Lopes CM, Amaral MH, Costa PC (2023) Surface-modified lipid nanocarriers for crossing the blood-brain barrier (BBB): a current overview of active targeting in brain diseases. Colloids Surf, B 221:11299910.1016/j.colsurfb.2022.112999 ↗
97. Waheed S, Li Z, Zhang F, Chiarini A, Armato U, Wu J (2022) Engineering nano-drug biointerface to overcome biological barriers toward precision drug delivery. J Nanobiotechnology 20(1):39510.1186/s12951-022-01605-4 ↗
98. Guntner AS, Peyrl A, Mayr L, Englinger B, Berger W, Slavc I et al (2020) Cerebrospinal fluid penetration of targeted therapeutics in pediatric brain tumor patients. Acta Neuropathol Commun 8(1):7810.1186/s40478-020-00953-2 ↗
99. Fan Y, Xu C, Deng N, Gao Z, Jiang Z, Li X et al (2023) Understanding drug nanocarrier and blood–brain barrier interaction based on a microfluidic microphysiological model. Lab Chip 23(7):1935–194410.1039/D2LC01077A ↗
100. Tan Q, Zhao S, Xu T, Wang Q, Lan M, Yan L et al (2022) Getting drugs to the brain: advances and prospects of organic nanoparticle delivery systems for assisting drugs to cross the blood-brain barrier. J Mater Chem B. 10(45):931410.1039/D2TB01440H ↗